Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based biopharmaceutical company, has announced an evaluation and potential licensing agreement with BioCopy AG, a research-driven biotechnology firm based in Basel, Switzerland. This agreement grants BioCopy access to a fully human library of TCR-mimic antibodies that target intracellular antigens. These antibodies are generated using Biocytogen’s proprietary RenTCR-mimic mice technology.
BioCopy will conduct an evaluation of these antibodies with the option to license them for developing innovative cancer treatments. The Swiss company plans to test the TCR-mimic antibodies against several promising intracellular tumor-associated antigens. Utilizing Biocytogen’s technology, BioCopy will apply its automated end-to-end platform for optimizing multispecific biotherapeutics, aiming to evolve these antibodies into next-generation cancer drugs. The financial details of the agreement have not been disclosed.- Flcube.com
